Rachel Lane was named CBO of Belharra Therapeutics in August 2023, following two years as Interim CBO, during which time she established Belharra’s flagship strategic collaboration deal with Genentech. Rachel brings over a decade of experience to the role leading R&D collaborations, transactions, and portfolio strategy across both private and public companies. She joins Belharra from Versant Ventures where she was responsible for new investments, including company creation and business development as CBO of Inception Therapeutics, Versant’s biotech incubator. Prior to Versant, Rachel also held diverse roles across the industry in business development at Calico Life Sciences and Ovid Therapeutics, early-stage investing at the Alzheimer’s Drug Discovery Foundation, and as a Wall Street sell-side analyst.
Rachel is a neurobiologist by training, gaining her PhD in cell and molecular biology from the University of Sheffield and postdoctoral training in neurobiology from the Icahn School of Medicine at Mount Sinai in New York.